Ticker >

Dr. Reddy''s Lab share price

Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  234k   1k   179

6699.95
+35.30 (0.53%)
BSE: Today, 09:09 AM

Price Summary

Today's High

₹ 6699.95

Today's Low

₹ 6699.95

52 Week High

₹ 7101

52 Week Low

₹ 5212.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

111806.72 Cr.

Enterprise Value

111382.72 Cr.

No. of Shares

16.69 Cr.

P/E

27.14

P/B

4.38

Face Value

₹ 5

Div. Yield

0.6 %

Book Value (TTM)

₹  1529.67

CASH

1216.9 Cr.

DEBT

792.9 Cr.

Promoter Holding

26.65 %

EPS (TTM)

₹  246.88

Sales Growth

14.86%

ROE

19.54 %

ROCE

25.52%

Profit Growth

66.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 38 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.86%
3 Year13.43%
5 Year12.89%

Profit Growth

1 Year66.18%
3 Year25.7%
5 Year27.73%

ROE%

1 Year19.54%
3 Year14.12%
5 Year15.45%

ROCE %

1 Year25.52%
3 Year18.7%
5 Year18.5%

Debt/Equity

0.0329

Price to Cash Flow

32.41

Interest Cover Ratio

266.656

CFO/PAT (5 Yr. Avg.)

1.10892490932047

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 26.65 0
Mar 2024 26.65 0
Dec 2023 26.65 0
Sep 2023 26.66 0
Jun 2023 26.69 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 25.6955975183994% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 266.656.
  • The Company has been maintaining an effective average operating margins of 24.1972820284217% in the last 5 years.
  • Company’s PEG ratio is 0.411302857874334.
  • The company has an efficient Cash Conversion Cycle of 18.7778 days.
  • Company has a healthy liquidity position with current ratio of 3.2145.
  • The company has a good cash flow management; CFO/PAT stands at 1.10892490932047.

 Limitations

  • The company has shown a poor revenue growth of 13.4331549527408% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 5437.3 4838.7 4103 5104.8 5841.2
Total Expenditure 3209.6 3209.6 3446.7 3726.2 3888.2
Operating Profit 2227.7 1629.1 656.3 1378.6 1953
Other Income 233.6 223.1 227.6 212.7 217.8
Interest 4.5 5.8 5.6 5.9 7.1
Depreciation 237.2 245.8 246.4 246.2 249.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 2219.6 1600.6 631.9 1339.2 1913.9
Tax 580.2 408 156.7 304.4 496.7
Profit After Tax 1639.4 1192.6 475.2 1034.8 1417.2
Adjusted EPS (Rs) 98.4 71.5 28.49 62.04 84.96

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 11850.4 13349.1 14405.2 16962.5 19483.8
Total Expenditure 8980.8 10212.3 11811.1 12747.7 13557.4
Operating Profit 2869.6 3136.8 2594.1 4214.8 5926.4
Other Income 743.2 801.1 482 591.3 862.3
Interest 47.8 46.7 38 16.9 21.8
Depreciation 789.2 835 814.3 923.2 975.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 2775.8 3056.2 2223.8 3866 5791.3
Tax -161.9 869.8 600.6 1253.2 1449.3
Net Profit 2937.7 2186.4 1623.2 2612.8 4342
Adjusted EPS (Rs.) 176.76 131.39 97.55 156.83 260.31

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 83.1 83.2 83.2 83.3 83.4
Total Reserves 15108.8 16900.5 18253 20390.9 24157.4
Borrowings 19.3 17.7 19.7 28.6 49.5
Other N/C liabilities -528.8 -186.9 75.2 432.3 530.9
Current liabilities 4180.5 4560.3 6045.1 4439.7 5538.1
Total Liabilities 18862.9 21374.8 24476.2 25374.8 30359.3
Assets
Net Block 4433.9 5844.3 6150.5 7195.3 7589.1
Capital WIP 384.1 877.1 1186.4 899.1 1171.9
Intangible WIP 27.7 23.7 13.9 25.3 39.1
Investments 3367.1 3392.2 3018.7 3248.6 3216.3
Loans & Advances 542 293.2 409.8 324.6 507.2
Other N/C Assets 1.4 0.1 202.6 0 33.4
Current Assets 10106.7 10944.2 13494.3 13681.9 17802.3
Total Assets 18862.9 21374.8 24476.2 25374.8 30359.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2775.8 3056.2 2223.8 3866 5791.3
Adjustment 681.8 273.3 845.1 1045.8 602
Changes in Assets & Liabilities -1141.5 632.7 -1241.4 923.7 -1624.1
Tax Paid -476.9 -448 -488.8 -782.7 -1319.5
Operating Cash Flow 1839.2 3514.2 1338.7 5052.8 3449.7
Investing Cash Flow -1689.2 -1453.6 -1990.1 -3403.1 -3428.7
Financing Cash Flow -224.1 -794.3 505.5 -2696.9 68.1
Net Cash Flow -74.1 1266.3 -145.9 -1047.2 89.1

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 26.69 26.66 26.65 26.65 26.65
anuradha gunupati 0.01 0.01 0.01 0.01 0.01
g v prasad - - - - 11.52
gunupati venkateswara pra... 1.53 1.52 1.52 1.52 1.52
kallam satish reddy huf 3.32 3.31 3.31 3.31 3.31
samrajyam reddy kallam 0.67 0.67 0.67 0.67 0.67
satish reddy kallam 0.54 0.54 0.54 0.54 9.61
aps trust 20.62 20.59 20.59 20.59 -
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 73.31 73.34 73.35 73.35 73.35
first sentier investors i... 2.20 2.32 2.32 2.32 2.32
hdfc trustee company ltd.... 1.77 1.75 1.81 1.62 1.75
icici prudential value di... - - - - 1.17
investor education and pr... - - - - 0.20
life insurance corporatio... 9.72 7.34 5.16 5.05 5.52
mirae asset nifty india m... - - - - 1.11
nippon life india trustee... - - - - 1.02
nps trust-a/c sbi pension... - 2.09 2.19 2.30 2.53
sbi nifty index fund - - - - 1.29
government of singapore 1.24 1.21 1.07 1.02 -
investor education and pr... 0.14 0.14 0.20 0.20 -
sbi-etf nifty 50 1.68 1.67 1.46 1.42 -
hdfc life insurance compa... 1.04 1.04 - - -
nps trust-a/c hdfc pensio... 2.13 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr. Reddy’s Laboratories informs about incorporation of step down wholly-owned subsidiary5 Oct 2024, 1:08PM Dr. Reddy's Laboratories’ arm incorporates new wholly-owned subsidiary5 Oct 2024, 1:01PM Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences 3 Oct 2024, 9:38AM Dr. Reddy's makes investment of $620 million in DRL SA 28 Sep 2024, 2:50PM Dr. Reddy’s Laboratories informs about disclosure 26 Sep 2024, 9:48AM USFDA completes GMP inspection at Dr. Reddy's Laboratories’ R&D centre20 Sep 2024, 6:10PM Dr. Reddy’s Laboratories informs about disclosure20 Sep 2024, 5:36PM Dr. Reddy's gets EIR for API manufacturing facility in Andhra Pradesh6 Sep 2024, 10:42AM Dr. Reddy’s Laboratories informs about update6 Sep 2024, 10:20AM Dr. Reddy's Laboratories’ arm recalling Ibuprofen tablets in multiple strengths in US market5 Sep 2024, 12:30PM USFDA completes Pre-Approval Inspection at Dr. Reddy’s Srikakulam formulations manufacturing facility 24 Aug 2024, 11:49AM Dr. Reddy’s Laboratories informs about update on inspection12 Aug 2024, 9:54AM Dr. Reddy's Laboratories gets EIR for formulations manufacturing facilities in Visakhapatnam12 Aug 2024, 9:30AM Dr. Reddy's Laboratories’ arm makes investment in Clean Renewable Energy KK 2A2 Aug 2024, 9:47AM Dr. Reddy’s Laboratories to infuse fund in Switzerland subsidiary29 Jul 2024, 11:07AM Dr. Reddy's Laboratories reports marginal fall in Q1 consolidated net profit29 Jul 2024, 10:14AM Dr. Reddy’s Laboratories informs about press release29 Jul 2024, 9:42AM Dr. Reddy's Lab - Quaterly Results27 Jul 2024, 4:12PM Dr. Reddy's Lab - Quaterly Results27 Jul 2024, 4:12PM Dr. Reddy's Lab - Quaterly Results27 Jul 2024, 4:12PM Dr. Reddy's Laboratories’ arm enters into definitive agreement with Haleon plc 27 Jun 2024, 11:28AM Dr. Reddy’s Laboratories informs about disclosure 27 Jun 2024, 9:53AM Dr. Reddy's Laboratories’ arm, Ingenus Pharmaceuticals enter into license agreement13 Jun 2024, 10:13AM Dr Reddy's Laboratories submits analyst meet intimation 10 Jun 2024, 12:44PM USFDA completes GMP inspection at Dr. Reddy's API manufacturing facility in Andhra Pradesh 8 Jun 2024, 1:00PM Dr. Reddy's Laboratories’ Aurigene inaugurates biologics facility in Hyderabad 4 Jun 2024, 9:37AM Dr. Reddy's Laboratories’ step down arm inks distribution agreement with Novartis Pharma27 May 2024, 4:44PM Dr. Reddy's makes investment of Rs 650 crore in Aurigene Oncology 25 May 2024, 4:16PM Dr. Reddy’s Laboratories informs about disclosure 24 May 2024, 12:14PM Dr. Reddy's Laboratories’ arm recalling Javygtor Powder for Oral Solution in US21 May 2024, 11:10AM Dr. Reddy’s Laboratories informs about audio recordings of earnings call8 May 2024, 10:31AM Dr. Reddy's Laboratories reports 36% rise in Q4 consolidated net profit7 May 2024, 4:52PM Dr. Reddy's Lab - Quaterly Results7 May 2024, 4:10PM Dr. Reddy's Lab - Quaterly Results7 May 2024, 4:10PM Dr. Reddy's Lab - Quaterly Results7 May 2024, 4:10PM Dr. Reddy's Laboratories launches Doxycycline Capsules 3 May 2024, 5:40PM Dr. Reddy’s, Nestle India enter into definitive agreement to form joint venture25 Apr 2024, 12:58PM Dr. Reddy’s issues voluntary nationwide recall of Sapropterin Dihydrochloride Powder for Oral Solution 24 Apr 2024, 10:00AM Dr.Reddy's Laboratories submits certificate19 Apr 2024, 5:20PM Dr. Reddy’s Laboratories’ arm to sell entire stake in Dr. Reddy’s Venezuela C.A., Venezuela15 Apr 2024, 9:50AM Dr. Reddy’s launches drug-free migraine management wearable device Nerivio in Germany 10 Apr 2024, 4:30PM Dr. Reddy's, Bayer sign marketing, distribution agreement for second brand of Vericiguat in India5 Apr 2024, 6:10PM Dr. Reddy's Laboratories enters into exclusive partnership with Sanofi Healthcare India28 Mar 2024, 10:28AM Dr. Reddy's Laboratories enters into license agreement with Pharmazz22 Mar 2024, 4:46PM Dr. Reddy’s Laboratories launches Versavo in United Kingdom19 Mar 2024, 2:51PM DR Reddy's Laboratories informs about press release 19 Mar 2024, 2:50PM Dr. Reddy's Laboratories incorporates wholly owned subsidiary15 Mar 2024, 12:00PM Dr. Reddy’s Laboratories informs about allotment of equity shares under ESOP15 Mar 2024, 9:49AM Dr Reddy's Laboratories informs about newspaper publication7 Mar 2024, 5:21PM Dr.Reddy's Laboratories informs about analyst meet26 Feb 2024, 3:12PM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time. Dr. Reddy''s Lab stock price today is Rs 6659.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Reddy''s Lab cash from the operating activity was Rs 3449.7 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.0329 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was 65.9827 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 30.4170644330162 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 19.5418 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Reddy''s Lab is Rs 6659.9. One can use valuation calculators of ticker to know if Dr. Reddy''s Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Reddy''s Lab

Dr. Reddy''s Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Dr. Reddy's Laboratories Ltd. is a leading Indian pharmaceutical company specializing in the production of generic drugs and active pharmaceutical ingredients. In this article, we will provide a comprehensive analysis of Dr. Reddy's Laboratories Ltd.'s stock from a long-term investor's perspective. We will cover various topics such as the company's share price, balance sheet, annual report, dividend, quarterly results, stock price trends, price charts, latest news, conference call (concall) insights, transcripts, investor presentations, promoters, and shareholders.

Dr. Reddy's Laboratories Ltd., a prominent Indian pharmaceutical company, focuses on producing generic drugs and active pharmaceutical ingredients. This article offers a thorough analysis of Dr. Reddy's Laboratories Ltd.'s stock, tailored for long-term investors. We will delve into the share price trends, balance sheet, annual reports, dividends, quarterly results, stock price movements, price charts, latest news, concall insights, transcripts, investor presentations, promoters, and shareholders to provide a holistic view of the company's financial health and growth prospects.

Dr. Reddy''s Laboratories Ltd. Share Price:

Dr. Reddy's Laboratories Ltd.'s share price is a key indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s share price and identify any trends or patterns. The company's share price has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Balance Sheet:

Dr. Reddy's Laboratories Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and inventory, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s balance sheet and identify any red flags. The company's balance sheet has been strong over the past few years, reflecting the company's ability to generate cash and manage its liabilities.

Dr. Reddy''s Laboratories Ltd. Annual Report:

Dr. Reddy's Laboratories Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Dividend:

Dr. Reddy's Laboratories Ltd. pays dividends to its shareholders. The company has a consistent dividend policy and pays dividends regularly. Long-term investors should consider this when evaluating Dr. Reddy's Laboratories Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Dr. Reddy''s Laboratories Ltd. Quarterly Results:

Dr. Reddy's Laboratories Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Dr. Reddy''s Laboratories Ltd. Stock Price:

The stock price of Dr. Reddy's Laboratories Ltd. is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Dr. Reddy's Laboratories Ltd.'s stock price and identify potential buying opportunities. The stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Dr. Reddy's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Dr. Reddy''s Laboratories Ltd. News:

Keeping up to date with the latest news about Dr. Reddy's Laboratories Ltd. is important for investors. Our website provides the latest news about Dr. Reddy's Laboratories Ltd. from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Dr. Reddy''s Laboratories Ltd. Concall:

Dr. Reddy's Laboratories Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Dr. Reddy's Laboratories Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Dr. Reddy''s Laboratories Ltd. Transcripts:

Transcripts of Dr. Reddy's Laboratories Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Investor Presentations:

Dr. Reddy's Laboratories Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Dr. Reddy's Laboratories Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Dr. Reddy''s Laboratories Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Dr. Reddy's Laboratories Ltd.'s promoters include Dr. Reddy's family and entities related to them. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Dr. Reddy's Laboratories Ltd. are relatively stable, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Shareholders:

Dr. Reddy's Laboratories Ltd. has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Dr. Reddy's Laboratories Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Dr. Reddy's Laboratories Ltd. is diverse, which is a positive sign for long-term investors.

Dr. Reddy''s Laboratories Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Dr. Reddy's Laboratories Limited ROCE

The Return on Capital Employed (ROCE) for Dr. Reddy's Laboratories Limited can be found in the financials table above. This ratio helps in assessing how efficiently the company is utilizing its capital to generate profits. A higher ROCE indicates efficient capital allocation and better profitability.

Dr. Reddy's Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) figure for Dr. Reddy's Laboratories Limited is available for reference in the above financials table. EBITDA provides insight into the company's operational performance without the impact of certain accounting factors like interest and taxes.

Dr. Reddy's Laboratories Limited DPS

Dividends Per Share (DPS) data can be found in the financials section of this page. DPS represents the amount of dividends each shareholder receives per share owned. It is an important metric for investors looking for steady income from their investments.

Dr. Reddy's Laboratories Limited EPS

Earnings Per Share (EPS) for Dr. Reddy's Laboratories Limited is provided in the financials section above. EPS indicates the company's profitability on a per-share basis, giving investors an idea of the company's earning power and performance relative to its outstanding shares.

Read More
X